TCERG1 regulates alternative splicing of the Bcl-x gene by modulating the rate of RNA polymerase II transcription

Molecular and Cellular Biology

Volumn 32, Issue 4, 2012, Pages 751-762

  Montes, Marta ^a   Cloutier, Alexandre ^b   Sánchez Hernández, Noemí ^a   Michelle, Laetitia ^b   Lemieux, Bruno ^b   Blanchette, Marco ^c   Hernández Munain, Cristina ^a   Chabot, Benoit ^b   Suñé, Carlos ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c STOWERS INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NUCLEAR FACTOR; PROTEIN BCL X; PROTEIN TCERG1; RNA POLYMERASE II; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; EXON; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROMOTER REGION; RNA SEQUENCE; RNA SPLICING; RNA SYNTHESIS;

ALTERNATIVE SPLICING; APOPTOSIS; BCL-X PROTEIN; EXONS; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HELA CELLS; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; REGULATORY ELEMENTS, TRANSCRIPTIONAL; RNA POLYMERASE II; RNA SPLICE SITES; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ELONGATION FACTORS;

EID: 84856774960     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06255-11     Document Type: Article

References (71)

1. Alexander RD, Innocente SA, Barrass JD, Beggs JD. 2010. Splicingdependent RNA polymerase pausing in yeast. Mol. Cell 40:582-593.
2. Allo M, et al. 2009. Control of alternative splicing through siRNAmediated transcriptional gene silencing. Nat. Struct. Mol. Biol. 16: 717-724.
3. Boise LH, et al. 1993. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608.
4. Bourquin JP, et al. 1997. A serine/arginine-rich nuclear matrix cyclophilin interacts with the C-terminal domain of RNA polymerase II. Nucleic Acids Res. 25:2055-2061.
5. Caceres JF, Kornblihtt AR. 2002. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 18:186-193.
6. Carrillo Oesterreich F, Preibisch S, Neugebauer KM. 2010. Global analysis of nascent RNA reveals transcriptional pausing in terminal exons. Mol. Cell 40:571-581.
7. Carty SM, Goldstrohm AC, Suñé C, Garcia-Blanco MA, Greenleaf AL. 2000. Protein-interaction modules that organize nuclear function: FF domains of CA150 bind the phosphoCTD of RNA polymerase II. Proc. Natl. Acad. Sci. U. S. A. 97:9015-9020.
8. Chapman RD, Palancade B, Lang A, Bensaude O, Eick D. 2004. The last CTD repeat of the mammalian RNA polymerase II large subunit is important for its stability. Nucleic Acids Res. 32:35-44.
9. Chavez S, Garcia-Rubio M, Prado F, Aguilera A. 2001. Hpr1 is preferentially required for transcription of either long or G+C-rich DNA sequences in Saccharomyces cerevisiae. Mol. Cell. Biol. 21:7054-7064.
10. Chen Y, Chafin D, Price DH, Greenleaf AL. 1996. Drosophila RNA polymerase II mutants that affect transcription elongation. J. Biol. Chem. 271:5993-5999.
11. Cheng D, Cote J, Shaaban S, Bedford MT. 2007. The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. Mol. Cell 25:71-83.
12. Coulter DE, Greenleaf AL. 1985. A mutation in the largest subunit of RNA polymerase II alters RNA chain elongation in vitro. J. Biol. Chem. 260:13190-13198.
13. Damgaard CK, et al. 2008. A 5′ splice site enhances the recruitment of basal transcription initiation factors in vivo. Mol. Cell 29:271-278.
14. Deckert J, et al. 2006. Protein composition and electron microscopy structure of affinity-purified human spliceosomal B complexes isolated under physiological conditions. Mol. Cell. Biol. 26:5528-5543.
15. de la Mata M, Kornblihtt AR. 2006. RNA polymerase II C-terminal domain mediates regulation of alternative splicing by SRp20. Nat. Struct. Mol. Biol. 13:973-980.
16. de la Mata M, et al. 2003. A slow RNA polymerase II affects alternative splicing in vivo. Mol. Cell 12:525-532.
17. Eperon LP, Graham IR, Griffiths AD, Eperon IC. 1988. Effects of RNA secondary structure on alternative splicing of pre-mRNA: is folding limited to a region behind the transcribing RNA polymerase? Cell 54:393-401.
18. Furger A, O'Sullivan JM, Binnie A, Lee BA, Proudfoot NJ. 2002. Promoter proximal splice sites enhance transcription. Genes Dev. 16: 2792-2799.
19. Garcia-Blanco MA, Baraniak AP, Lasda EL. 2004. Alternative splicing in disease and therapy. Nat. Biotechnol. 22:535-546.
20. Garneau D, Revil T, Fisette JF, Chabot B. 2005. Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. J. Biol. Chem. 280:22641-22650.
21. Gerber HP, et al. 1995. RNA polymerase II C-terminal domain required for enhancer-driven transcription. Nature 374:660-662.
22. Gilchrist DA, et al. 2010. Pausing of RNA polymerase II disrupts DNAspecified nucleosome organization to enable precise gene regulation. Cell 143:540-551.
23. Goldstrohm AC, Albrecht TR, Suñé C, Bedford MT, Garcia-Blanco MA. 2001. The transcription elongation factor CA150 interacts withRNApolymerase II and the pre-mRNA splicing factor SF1. Mol. Cell. Biol. 21:7617-7628.
24. Goldstrohm AC, Greenleaf AL, Garcia-Blanco MA. 2001. Co-transcriptional splicing of pre-messenger RNAs: considerations for the mechanism of alternative splicing. Gene 277:31-47.
25. Hendrix DA, Hong JW, Zeitlinger J, Rokhsar DS, Levine MS. 2008. Promoter elements associated with RNA Pol II stalling in the Drosophila embryo. Proc. Natl. Acad. Sci. U. S. A. 105:7762-7767.
26. Howe KJ, Kane CM, Ares M, Jr. 2003. Perturbation of transcription elongation influences the fidelity of internal exon inclusion in Saccharomyces cerevisiae. RNA 9:993-1006.
27. Kadener S, et al. 2001. Antagonistic effects of T-Ag and VP16 reveal a role for RNA pol II elongation on alternative splicing. EMBO J. 20:5759-5768.
28. Kim E, Du L, Bregman DB, Warren SL. 1997. Splicing factors associate with hyperphosphorylated RNA polymerase II in the absence of premRNA. J. Cell Biol. 136:19-28.
29. Kornblihtt AR. 2007. Coupling transcription and alternative splicing. Adv. Exp. Med. Biol. 623:175-189.
30. Levine M. 2011. Paused RNA polymerase II as a developmental checkpoint. Cell 145:502-511.
31. Li H, et al. 2009. The sequence alignment/map format and SAM tools. Bioinformatics 25:2078 -2079.
32. Licatalosi DD, Darnell RB. 2006. Splicing regulation in neurologic disease. Neuron 52:93-101.
33. Lin KT, Lu RM, Tarn WY. 2004. The WW domain-containing proteins interact with the early spliceosome and participate in pre-mRNA splicing in vivo. Mol. Cell. Biol. 24:9176-9185.
34. Lin S, Coutinho-Mansfield G, Wang D, Pandit S, Fu XD. 2008. The splicing factor SC35 has an active role in transcriptional elongation. Nat. Struct. Mol. Biol. 15:819-826.
35. Listerman I, Sapra AK, Neugebauer KM. 2006. Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells. Nat. Struct. Mol. Biol. 13:815-822.
36. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T. 2011. Epigenetics in alternative pre-mRNA splicing. Cell 144:16 -26.
37. Makarov EM, et al. 2002. Small nuclear ribonucleoprotein remodeling during catalytic activation of the spliceosome. Science 298:2205-2208.
38. McCracken S, et al. 1997a. The C-terminal domain of RNA polymerase II couples mRNA processing to transcription. Nature 385:357-361.
39. Meininghaus M, Chapman RD, Horndasch M, Eick D. 2000. Conditional expression of RNA polymerase II in mammalian cells. Deletion of the carboxyl-terminal domain of the large subunit affects early steps in transcription. J. Biol. Chem. 275:24375-24382.
40. Misteli T, Spector DL. 1999. RNA polymerase II targets pre-mRNA splicing factors to transcription sites in vivo. Mol. Cell 3:697-705.
41. Moore MJ, Proudfoot NJ. 2009. Pre-mRNA processing reaches back to transcription and ahead to translation. Cell 136:688-700.
42. Morris DP, Greenleaf AL. 2000. The splicing factor, Prp40, binds the phosphorylated carboxyl-terminal domain of RNA polymerase II. J. Biol. Chem. 275:39935-39943.
43. Mortillaro MJ, et al. 1996. A hyperphosphorylated form of the large subunit of RNA polymerase II is associated with splicing complexes and the nuclear matrix. Proc. Natl. Acad. Sci. U. S. A. 93:8253-8257.
44. Munoz MJ, de la Mata M, Kornblihtt AR. 2010. The carboxy terminal domain of RNA polymerase II and alternative splicing. Trends Biochem. Sci. 35:497-504.
45. Munoz MJ, et al. 2009. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 137:708-720.
46. Nasim FU, Hutchison S, Cordeau M, Chabot B. 2002. High-affinity hnRNP A1 binding sites and duplex-forming inverted repeats have similar effects on 5′ splice site selection in support of a common looping out and repression mechanism. RNA. 8:1078-1089.
47. Neubauer G, et al. 1998. Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex. Nat. Genet. 20:46-50.
48. Nogues G, Kadener S, Cramer P, Bentley D, Kornblihtt AR. 2002. Transcriptional activators differ in their abilities to control alternative splicing. J. Biol. Chem. 277:43110-43114.
49. Oesterreich FC, Bieberstein N, Neugebauer KM. 2011. Pause locally, splice globally. Trends Cell. Biol. 21:328-335.
50. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. 2008. Deep surveying of alternative splicing complexity in the human transcriptome by highthroughput sequencing. Nat. Genet. 40:1413-1415.
51. Pearson JL, Robinson TJ, Munoz MJ, Kornblihtt AR, Garcia-Blanco MA. 2008. Identification of the cellular targets of the transcription factor TCERG1 reveals a prevalent role in mRNA processing. J. Biol. Chem. 283:7949-7961.
52. Rappsilber J, Ryder U, Lamond AI, Mann M. 2002. Large-scale proteomic analysis of the human spliceosome. Genome Res. 12:1231-1245.
53. Resnekov O, Kessler M, Aloni Y. 1989. RNA secondary structure is an integral part of the in vitro mechanism of attenuation in simian virus 40. J. Biol. Chem. 264:9953-9959.
54. Revil T, Pelletier J, Toutant J, Cloutier A, Chabot B. 2009. Heterogeneous nuclear ribonucleoprotein K represses the production of proapoptotic Bcl-xS splice isoform. J. Biol. Chem. 284:21458-21467.
55. Revil T, et al. 2007. Protein kinase C-dependent control of Bcl-x alternative splicing. Mol. Cell. Biol. 27:8431-8441.
56. Roberts GC, Gooding C, Mak HY, Proudfoot NJ, Smith CW. 1998. Co-transcriptional commitment to alternative splice site selection. Nucleic Acids Res. 26:5568-5572.
57. Sánchez-Alvarez M, Goldstrohm AC, Garcia-Blanco MA, Suñé C. 2006. Human transcription elongation factor CA150 localizes to splicing factorrich nuclear speckles and assembles transcription and splicing components into complexes through its amino and carboxyl regions. Mol. Cell. Biol. 26:4998-5014.
58. Sánchez-Alvarez M, Montes M, Sánchez-Hernández N, Hernández-Munain C, Suñé C. 2010. Differential effects of sumoylation on transcription and alternative splicing by transcription elongation regulator 1 (TCERG1). J. Biol. Chem. 285:15220-15233.
59. Shkreta L, Michelle L, Toutant J, Tremblay ML, Chabot B. 2011. The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x. J. Biol. Chem. 286:331-340.
60. Singh J, Padgett RA. 2009. Rates of in situ transcription and splicing in large human genes. Nat. Struct. Mol. Biol. 16:1128 -1133.
61. Smith MJ, Kulkarni S, Pawson T. 2004. FF domains of CA150 bind transcription and splicing factors through multiple weak interactions. Mol. Cell. Biol. 24:9274-9285.
62. Suñé C, Garcia-Blanco MA. 1999. Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA-box-dependent manner. Mol. Cell. Biol. 19:4719-4728.
63. Suñé C, et al. 1997. CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription. Mol. Cell. Biol. 17:6029-6039.
64. Svotelis A, Gevry N, Gaudreau L. 2009. Chromatin immunoprecipitation in mammalian cells. Methods Mol. Biol. 543:243-251.
65. Tous C, et al. 2011. A novel assay identifies transcript elongation roles for the Nup84 complex and RNA processing factors. EMBO J. 30:1953-1964.
66. Wang ET, et al. 2008. Alternative isoform regulation in human tissue transcriptomes. Nature 456:470-476.
67. Wang GS, Cooper TA. 2007. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat. Rev. Genet. 8:749-761.
68. Wang KC, Cheng AL, Chuang SE, Hsu HC, Su IJ. 2000. Retinoic acid-induced apoptotic pathway in T-cell lymphoma: Identification of four groups of genes with differential biological functions. Exp. Hematol. 28:1441-1450.
69. Wilhelm BT, et al. 2011. Differential patterns of intronic and exonic DNA regions with respect to RNA polymerase II occupancy, nucleosome density and H3K36me3 marking in fission yeast. Genome Biol. 12:R82.
70. Yang X, et al. 1994. The A1 and A1B proteins of heterogeneous nuclear ribonucleoparticles modulate 5= splice site selection in vivo. Proc. Natl. Acad. Sci. U. S. A. 91:6924-6928.
71. Yuryev A, et al. 1996. The C-terminal domain of the largest subunit of RNA polymerase II interacts with a novel set of serine/arginine-rich proteins. Proc. Natl. Acad. Sci. U. S. A. 93:6975-6980.